CRDF earnings analysis
What we found in CRDF's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q extract provides no current-quarter income statement, balance-sheet, cash-flow, segment, or quantitative guidance data, so financial trends cannot be independently assessed from the filing text provided. The principal update is a substantial escalation in legal and operational risk: Cardiff is litigating 1 dispute with NMS over rights integral to onvansertib. Loss of those rights, inability to obtain injunctive relief, and litigation that may last multiple years could materially disrupt operations, increase costs, and impair financing flexibility.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls deemed effective
- Management concluded that disclosure controls were effective as of June 30, 2026, providing reasonable assurance that required information was reported within SEC time periods.
- No material control changes
- The company reported no change in internal control over financial reporting during the 3 months ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pending NMS litigation threatens license
- The 10-Q adds material litigation risk relating to 1 pending lawsuit against NMS. The company states that an adverse determination could result in loss of the licensed rights and materially affect its business, financial condition, results of operations, and prospects.
- Potential loss of onvansertib rights
- The filing states that the NMS Agreement provided exclusive rights integral to onvansertib and that termination could require the company to cease or significantly curtail operations, seek alternative technology, or impair related assets.
- Prolonged litigation may consume cash
- The company says the litigation could take multiple years at the trial-court level, with additional time for appeals, while also generating significant legal fees and diverting senior-management resources.
What they said about what is next.
The supplied 10-Q extract does not include MD&A, financial statements, or a quantitative outlook. Prior cash-runway commentary from the July 16, 2026 8-K is not reaffirmed in the supplied filing.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Cardiff Oncology reported a significant decline in revenues in Q1 2026, totaling $41,000, compared to $109,000 in Q1 2025. The gross margin remained steady at 100%, but the company reported continued substantial…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CRDF makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever